Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer

Stopped early · Phase 3

Conditions studied: Colorectal Cancer, Diarrhea

In brief

RATIONALE: Octreotide may be effective in preventing diarrhea that is caused by treatment with irinotecan. PURPOSE: Randomized phase III trial to study the effectiveness of octreotide in preventing diarrhea in patients who are receiving irinotecan for metastatic colon cancer.

Key facts

Study ID

NCT00006269

Run by

Novartis

People needed

89

Starts

1999-12-01

Last updated by the study team

2012-05-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Novartis Pharmaceuticals Corporation — East Hanover, New Jersey, United States
• Theradex — Princeton, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.